Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Osmonar
- Development stage
- Unknown
- Lead developer
- Laboratori Baldacci
- Administration
- Intranasal
01
Overview
Osmonar is an intranasal gel medical device developed by Laboratori Baldacci for the treatment of nasal mucosa dryness (dry rhinitis) and irritation, as well as upper respiratory tract conditions. It is formulated with a synergistic combination of pyrrolidone carboxylic acid (PCA) and hyaluronic acid (sodium salt). PCA acts as an osmoprotective and moisturizing agent, while hyaluronic acid provides mucoadhesive, hygroscopic, and viscosifying properties. Together, they form a protective barrier film over the nasal mucosa, shielding it from external irritants like dust and allergens, promoting mucosal rehydration, and facilitating the physiological repair and recovery of respiratory function.
- Brand names
- Osmonar
- Other names
- Osmonar Gel Nasalepyrrolidone carboxylic acid + hyaluronic acidpyrrolidone carboxylic acid and hyaluronic acid nasal gel
Beyond the preview
Go deeper on Osmonar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Osmonar.